Antibodies represent established affinity reagents for use in the regulatory bioanalysis of biologics. Yet, these reagents are associated with limitations that often present challenges with supply, stability and batch-to-batch variation on assay performance.
Our new application note outlines our established development and characterisation process for Affimer binders to four of the leading therapeutic antibodies- Trastuzumab, Rituximab, Adalimumab and Ipilimumab- for use as PK assay reagents.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.